Calendar

Lennar had a valid after-close date and some operational positives, including sequentially improved gross margin, lower cycle time, and a solid balance sheet, but consensus still expected EPS of $1.31 and revenue of $8.396 billion against a weak housing backdrop; the recent rebound was not enough to offset the absence of positive estimate revisions and the lack of clean accumulation.

Rejected because FedEx company IR shows fiscal fourth-quarter results were reported on June 23, 2026 and the next earnings call was scheduled for October 28, so the supplied September 16 event is not a valid pre-earnings event.

Rejected because AAR reported fiscal fourth-quarter 2026 results on July 21, 2026 and its investor-events page showed no upcoming earnings event corresponding to September 21.

AutoZone had a strong prior quarter, positive same-store sales, and a small three-month revenue-estimate improvement, but the current whisper was below consensus, EPS revisions were flat to slightly negative, the stock was down over five and twenty sessions, and the highest recent volume did not clear the 1.5x threshold on a clean accumulation day.

Thor Industries had a confirmed before-open date and some diversification support from European and supplier businesses, but EPS and revenue estimates were revised lower, management cut full-year EPS guidance, prior-quarter sales and gross margin declined, and the stock was weak into the print without verified accumulation.

KB Home had a confirmed date and a possible built-to-order operating improvement, but both EPS and revenue estimates were revised lower, prior-quarter deliveries, revenue, income, backlog, and average selling price were weak, and the stock remained sharply below late-August levels; the isolated high-volume rebound was not enough to establish an upside-surprise setup.

Rejected because Ferguson reported fiscal second-quarter 2026 results on August 10, 2026 and company materials indicated the next results were expected November 9, not September 22.

News coverage is sparse and largely limited to an earnings snapshot, an earnings-call summary, and the company’s Q2 results invitation. The company investor-relations page currently points to an August 26 release, so this appears to be an early or mis-timed scheduled follow-up rather than a completed T+3 post-earnings review. Missing analyst reaction, estimate revisions, and market-reaction evidence should lower confidence rather than be treated as positive.

The company’s August 20 SEC-filed earnings release confirms the Q2 beat, raised second-half outlook, and store-plan increase. Stored secondary coverage reported shares up approximately 4% after the print and cited divergent analyst target actions from UBS, Truist, and Barclays. No independent analyst-consensus series or later estimate revisions are available in the packet; social, options, short-interest, and employee-sentiment data are also unavailable. [#SEC-8K-2026-08-20] [#PR-EARNINGS-2026-08-21]

Post-print evidence is mixed. Investing.com reported adjusted EPS of $4.40 versus $4.23 expected, revenue of $26.0 billion versus $26.16 billion expected, and an initial 4.21% premarket rise to $224.71 from a $215.64 prior close ([Investing.com earnings coverage](https://www.investing.com/news/transcripts/earnings-call-transcript-lowes-tops-q2-eps-forecast-as-shares-rise-42-93CH-4867779)). The RankAlpha August 21 anchor was $216.09, indicating that the initial reaction did not hold. Analyst revision evidence is available but mostly consists of target cuts with retained positive ratings; social, options, short-interest, and employee-sentiment data remain unavailable.

Post-earnings coverage was directionally constructive, including reports that the shares rallied and outperformed on strong trading days. Exact post-print return attribution, analyst revisions, options data, short interest, employee sentiment, social coverage, and direct peer comparisons were unavailable. The primary-source evidence is strong, but the T+3 view remains tentative and monitoring-oriented rather than a high-conviction relative-value call.

Post-earnings tone is mixed rather than decisively bullish. The primary release is constructive on psoriasis efficacy, cash runway, LUMUS timing, and the NDA plan [#SEC-8K-2026-08-13], but the financial print and lonigutamab impairment weigh on sentiment. Secondary price history showed closes of $24.41 on August 13 (-4.46%), $23.99 on August 19 (-3.58%), and $22.86 on August 20 (-4.71%), followed by $24.17 on August 21 (+5.73%). Analyst revisions are available but mixed, with neutral reiterations alongside maintained buy targets. The deterministic prior remains negative across 5-day to 120-day horizons, supporting monitoring rather than chasing strength.

News tone is positive following the record Q3 result, above-outlook Q4 guidance, and reported Bernstein upgrade, but the verified market reaction was initially soft: ADI declined 0.89% on August 19 and 0.81% on August 20 before a modest premarket rebound on August 21. This mixed reaction and the limited available analyst revision set support a positive but valuation-sensitive monitoring view rather than a high-conviction breakout thesis. [Price history](https://stockanalysis.com/stocks/adi/history/)